drugset / Trial / NCT03198507
ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator
RandomizedParallel-groupTriple-blindTreatment
Summary
The "test and treat" strategy for treating dyspeptic patients who are H. pylori positive is rapidly becoming the standard of care. This study will test the effectiveness of RHB-105, a new triple therapy to treat H. pylori infection in dyspeptic patients against an active comparator.
Timeline
- Start
- 2017-06-18
- Primary completion
- 2018-10-24
- Completion
- 2018-12-13
Publications
- Howden CW, Sheldon KL, Almenoff JS, Chey WD. Pitfalls of Physician-Directed Treatment of Helicobacter pylori: Results from Two Phase 3 Clinical Trials and Real-World Prescribing Data. Dig Dis Sci. 2022 Sep;67(9):4382-4386. doi: 10.1007/s10620-021-07323-5. Epub 2021 Dec 4.
- Graham DY, Canaan Y, Maher J, Wiener G, Hulten KG, Kalfus IN. Rifabutin-Based Triple Therapy (RHB-105) for Helicobacter pylori Eradication: A Double-Blind, Randomized, Controlled Trial. Ann Intern Med. 2020 Jun 16;172(12):795-802. doi: 10.7326/M19-3734. Epub 2020 May 5.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rifabutin | Small molecule | 150 mg | Oral |
| Background | Amoxicillin | Other / unclassified | 3000 mg | Oral |
| Background | Omeprazole | Other / unclassified | 120 mg | Oral |
| Background | Riboflavin | Other / unclassified | 50 mg | — |